We previously demonstrated that ITF2357 and the related pan-HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) improve diastolic function in murine and feline models of hypertension, aging, and chronic pressure overload in association with enhanced myofibril relaxation (21, 38). Here, HDAC9 is linked to Hypertension.